Across TCGA pan-cancer cohorts, SAGE3P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated SAGE3P data layer compared with 12 for mass-spec protein.
The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SAGE3P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SAGE3P expression acts as an unfavorable survival marker.
BRCA are the cancer types where SAGE3P Mutation most reproducibly stratifies survival.